Key Insights

Highlights

Success Rate

93% trial completion (above average)

Published Results

82 trials with published results (5%)

Research Maturity

774 completed trials (50% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.8%

59 terminated out of 1553 trials

Success Rate

92.9%

+6.4% vs benchmark

Late-Stage Pipeline

12%

186 trials in Phase 3/4

Results Transparency

11%

82 of 774 completed with results

Key Signals

82 with results93% success59 terminated

Data Visualizations

Phase Distribution

735Total
Not Applicable (369)
Early P 1 (4)
P 1 (60)
P 2 (116)
P 3 (93)
P 4 (93)

Trial Status

Completed774
Unknown333
Recruiting183
Not Yet Recruiting104
Terminated59
Withdrawn57

Trial Success Rate

92.9%

Benchmark: 86.5%

Based on 774 completed trials

Clinical Trials (1553)

Showing 20 of 20 trials
NCT05930418Not ApplicableCompleted

Cardiovascular Magnetic Resonance Prognosticators in Pediatric Oncology Patients With Sepsis

NCT06854640Phase 1RecruitingPrimary

A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy

NCT07599644RecruitingPrimary

Sepsis Multiomic Analysis & Risk sTratification in China

NCT05136560Phase 1CompletedPrimary

Safety and Efficacy of Early Administration of Dexamethasone in High-risk Sepsis

NCT03334006Phase 2Recruiting

Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis

NCT06219135RecruitingPrimary

Evaluation of the Performance of the IDBIORIV Method in Pathogen Identification and Antibiotic Susceptibility Testing in Patients With Sepsis

NCT07634419Not ApplicableNot Yet Recruiting

Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress: the Lift RCT

NCT05900284Phase 2CompletedPrimary

Safety and Feasibility of Metformin for Sepsis Induced AKI

NCT01904188RecruitingPrimary

Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?

NCT07236463Phase 1Recruiting

Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate in Sepsis-Associated Acute Kidney Injury

NCT07629154RecruitingPrimary

Smart Discharges for Older Children

NCT05922371CompletedPrimary

ObsErvational Study of the Practical Cinical UTility of the NuQ.® H3.1 Nucleosome Levels in Adult Patients With Sepsis to Facilitate Early Diagnosis and Prognostication. (EPICETUS)

NCT07518303Phase 4Not Yet RecruitingPrimary

Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury

NCT06498336CompletedPrimary

miRNA in Septic Acute Kidney Injury

NCT07451886Phase 2RecruitingPrimary

Adjunctive Fludrocortisone in Septic Shock

NCT01530854CompletedPrimary

Plasma Free Fatty Acids in Risk Assessment of Sepsis in the Emergency Department: A Prospective Pilot Study

NCT07332325Phase 3Not Yet RecruitingPrimary

STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis

NCT07616817Enrolling By Invitation

Delphi Septic Shock: Sub-phenotypes Using Point-of-Care Ultrasound in Patients With Septic Shock

NCT07225257RecruitingPrimary

Recovery of Physical Function After Critical Illness In Older Adults

NCT07454421Phase 1Enrolling By InvitationPrimary

Racecadotril for Organ Injury in Sepsis Patients

Scroll to load more

Research Network

Activity Timeline